Lehmann W, Strauss M, Kiessling U, Graetz H, Koberling A, Langen P
Central Institute for Molecular Biology, Academy of Sciences, Berlin-Buch, GDR.
FEBS Lett. 1989 Feb 13;244(1):185-7. doi: 10.1016/0014-5793(89)81189-5.
A mammary-derived growth inhibitor (MDGI) inhibits the resumption of growth of stationary Ehrlich ascites carcinoma (EAC) cells in vitro. The present study shows that the resumption of growth is accompanied by a rapid increase of the steady state mRNA level of the proto-oncogenes c-fos, c-myc and c-ras, which is reduced by MDGI. EAC cells from the exponential growth phase insensitive to MDGI did not show a reduced RNA expression. The effect of MDGI represents a novel activity at the level of gene expression and suggests a link to exist between growth inhibition and the reduction of c-fos, c-myc and c-ras expression.
一种乳腺衍生生长抑制剂(MDGI)可在体外抑制静止期艾氏腹水癌(EAC)细胞的生长恢复。本研究表明,生长恢复伴随着原癌基因c-fos、c-myc和c-ras稳态mRNA水平的快速增加,而MDGI可降低这种增加。处于指数生长期且对MDGI不敏感的EAC细胞未显示出RNA表达降低。MDGI的作用代表了基因表达水平上的一种新活性,并提示生长抑制与c-fos、c-myc和c-ras表达降低之间存在联系。